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Purpose: The objective of this study was to determine the diagnostic
value of computed tomography (CT) and positron emission tomogra-
phy (PET)/CT for staging of malignant pleural mesothelioma (MPM)
in patients undergoing induction chemotherapy.
Methods: Sixty-two patients (median age, 61 years; female: n = 9) with
proven MPM underwent CT after induction chemotherapy. Of these,
28 underwent additional PET/CT. Extrapleural pneumonectomy was per-
formed for pathological TNM staging. Clinical TNM stage was assessed
by 3 independent readers. Relative and absolute underestimation and over-
estimation were compared with pathological tumor stage. Sensitivity, spec-
ificity, and accuracy for differentiation between stages T2 and T3 were
assessed. Interobserver agreement between the readers was analyzed (κ).
Results: Positron emission tomography/CT and CT underestimated
T stage in up to 30% of the cases. Positron emission tomography/CT
had a higher accuracy for tumor extent compared with CT (PET/CT:
0.92; CT: 0.84). The accuracy for nodal staging was higher for CT than
for PET/CT (PET/CT: 0.78; CT: 0.87). Concerning International Meso-
thelioma Interest Group classification, PET/CT improved the accuracy
of preoperative staging compared with CT (PET/CT: 0.91; CT: 0.82). In-
terobserver agreement was moderate for CT (0.48–0.62) and good for
PET/CT (0.64–0.83) for T staging. For nodal staging, interobserver agree-
ment was fair to moderate for CT and good for PET/CT (CT: 0.37–0.51;
PET/CT: 0.73–0.76).
Conclusions: Positron emission tomography/CT is more accurate and
has a lower interobserver variability for clinical intrathoracic staging
of MPM compared with CT. Nevertheless PET/CT underestimated
tumor stage in a substantial number of cases, showing the need for a
more accurate imaging technology or approach.
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C omputed tomography (CT), magnetic resonance imaging(MRI), and positron emission tomography combined with
CT (PET/CT) are the imaging modalities of choice for nonin-
vasive staging.1–3 In particular, CT is widely used for clinical
staging. Although imaging is essential to the diagnosis, assessment,
and monitoring of malignant pleural mesothelioma (MPM), the
complex morphology and growth pattern of MPM create unique
challenges for imaging acquisition and interpretation.4 Eachmodal-
ity, because of their differences in scientific basis and technical capa-
bility, contributes to a better understanding of the genesis, biology,
and biochemical response of MPM, allowing further development
of new treatment strategies.4 Whereas earlier studies have shown
that CT and MRI failed to accurately define TNM tumor stage,
the results of newer studies investigating the accuracy of CT,
PET/CT, and MRI for staging of MPM are more promising.3,5–8
Clinical staging in patients with MPM is important for deci-
sion making in terms of patient selection for multimodality treat-
ment, which currently offers the best survival.9 It is still unclear
which patients will benefit from either a systemic or surgical treat-
ment, as the management of this uncommon cancer is based on
small data sets from single-center, retrospective studies.10–12 To
determine treatment and prognosis and to make studies compa-
rable, a correct and uniform staging system is very important. At
least 5 systems for MPM are known in the literature.13 Early stag-
ing systems, like those from Butchard or Sugarbaker, do not use
the T, N, and M descriptors as applied in the classic TNM classi-
fication of tumors.12–14 In 1995, the International Mesothelioma
Interest Group (IMIG) introduced a new staging system based
on the TNM classification in accordance with previous staging
systems.15 This classification is similar to those for other solid
tumors. As shown by Rusch et al6 in the initial analysis of the
International Association for the Study of Lung Cancer (IASLC)/
IMIG database, there are concerns about the validity of the cur-
rent staging system as the grouping into classes for both T stage
and N stage does not reflect the tumor biology and behavior re-
garding the survival among different classes.
The objective of our study was to determine the diagnostic
value of CT and PET/CT for staging of patients with pleural
mesothelioma after induction chemotherapy. All patients had
subsequent surgery, which was used as the criterion standard for
the verification of imaging findings.
MATERIALS AND METHODS
A patient cohort of 62 patients undergoing induction chemo-
therapy followed by extrapleural pneumonectomy (EPP) over a
12-year period was identified and retrospectively analyzed. All
patients underwent CT after induction chemotherapy and before
EPP, which served as the standard of reference. None of these pa-
tients had distant metastases. Median interval between CT scan
and EPP was 16 days (0–28 days). Fifty-five percent (n = 34)
had previous talc pleurodesis, and 85% (n = 53) underwent medi-
astinoscopy prior to chemotherapy.
Contrast-enhanced CT scan was performed at a median of
16 days prior to EPP (0–28 days). Twenty-six of these 62 patients
(median age, 62 years [range, 38–69 years]; female: n = 4; male:
n = 22) had additional PET/CT scan prior to EPP. Median interval
between PET/CT scan and EPP was 17 days (1–41 days). Institu-
tional review board approval for data collection and analysis was
obtained. Informed consent was obtained from all patients.
The chest CT protocol consisted of a venous phase CTof the
chest using a scan delay of 100 seconds after starting contrast
agent application. This protocol was chosen based on the results
of a prior study.17 Computed tomography was performed with
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either a 64-section or 256-section CT scanner (Siemens Sensation
and Siemens Sensation Flash, Erlangen, Germany). Chest images
were reconstructed using a sharp-edged tissue convolution kernel
(B60f) and a medium-smooth soft tissue convolution kernel
(B30f) at a slice thickness of 2 mm and increment of 1.7 mm.
All patients were examined on 1 of 2 combined PET/CT
inline systems (Discovery STE or Discovery RX; GE Health-
care, Milwaukee, Wis). First, a low-dose CT scan was acquired
from the head to the pelvic floor using the following parameters:
140 kV, 40 mAs, 0.5 s/tube rotation, slice thickness of 4.25 mm.
Immediately after the CT acquisition, the PET emission scan
was acquired covering the same scan range with either 180 seconds
(Discovery STE, 3D mode) or 120 seconds (Discovery RX, 3D
mode) emission time per cradle position with 7-slice overlap (ma-
trix, 128  128). A total of 7 to 9 cradle positions were scanned,
resulting in a total PET acquisition time of 14 to 21 min. The CT
data used for the attenuation correction and the images were recon-
structed using a standard iterative algorithm (ordered subset expec-
tationmaximization). Patients were instructed to hold their breath in
normal expiration during the acquisition of the CT images. Positron
emission tomography raw data were not used for readout. No con-
trast media was given during the PET/CT procedure.
Imaging Assessment
Three independent observers assessed the CT images (1 expe-
rienced radiologist, 1 experienced thoracic surgeon, and 1 experi-
enced dual-board-certified nuclear medicine radiologist). The
readers were blinded to any clinical information and unaware of
pathologic staging or follow-up. The readers are further named
CT-R1, CT-R2, and CT-R3. The PET/CT images were assessed
by 3 independent observers (1 experienced radiologist and 2 ex-
perienced dual-board-certified nuclear medicine radiologists).
The readers are further named PET/CT-R1, PET/CT-R2, and
PET/CT-R3. Positron emission tomography/CT-R1 and PET/CT-
R3 were equal with CT-R1 and CT-R3. For the direct comparison
between CT and PET/CT, only the results of PET/CT-R1 and PET/
CT-R3 were used. A commercially available PACS System (Impax
5; Agfa Healthcare, Dübendorf, Switzerland) was used for read-
out. All readers could use Multiplanar reformation tool and
adjust window/level setting if necessary. Positron emission
tomography/CT images were fused before reading using a com-
mercially available workstation (Advantage Workstation, ver-
sion 4.5; GE Healthcare).
TNM staging was performed using the TNM classification
system for MPM based on the seventh edition of TNM classifi-
cation of malignant tumors.17 For each patient, the precise TNM
tumor stage was defined. Lymph nodes were considered as posi-
tive if the short-axis diameter was more than 1 cm. Pathological
TNM staging after EPP was used as reference.
Statistical Analysis
Relative and absolute underestimation or overestimation of
clinical tumor stage compared with pathological tumor stage
was calculated. Mean sensitivity, specificity, positive and negative
predictive value, and accuracy of CT and PET/CTof all 3 readers
were calculated (Analyse-it for Microsoft Excel, version 2.30;
Analyse-it Software, Ltd; http://analyse-it.com/; 2012). Underes-
timation was defined as false negative, and overestimation was
defined as false positive. Interobserver agreement between the
readers was tested using a weighted κ test. κ Values of 0.20
or less were considered as poor, κ values of 0.21 to 0.40 as fair,
κ values 0.41 to 0.60 asmoderate, κ values of 0.61 to 0.80 as good,
and κ values of 0.81 to 1.00 as excellent agreement.18
RESULTS
Patient Characteristics
Digitally available chest CT scans performed after induc-
tion chemotherapy and before EPP were available from 62 meso-
thelioma patients (median age, 61 years [range, 38–72 years];
female: n = 9; male: n = 53). Induction chemotherapy consisted
of 3 cycles of cisplatin and gemcitabine in 9 patients. Four years
into the study, the induction regimen was changed, with the re-
maining 53 patients receiving cisplatin and pemetrexed. The ma-
jority of patients had an epithelioid histotype, 63% (n = 39), 2%
(n = 1) sarcomatoid, and 35% (n = 22) biphasic histotype.
The distribution of the pathological T and N stages as well
as IMIG stages among the population is displayed in Table 1.
Computed Tomography
The sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy of CT for stage T4 disease were
40%, 95%, 66%, 87%, and 84% for CT-R1. Compared with path-
ological T staging, the number of correctly staged patients ranged
from 40 (CT-R2) to 44 patients (CT-R1). The tumor extent was
more often overestimated for stage T1 and T2 (CT-R1: n = 2
[3%], CT-R2: n = 3 [4.5%], CT-R3: n = 4 [6%]) and
underestimated for stages T3 and T4 (CT-R1 and CT-R3: n = 14
[22%], CT-R2: n = 17 [27%]) (Fig. 1, Table 2).
For nodal staging, the sensitivity, specificity, positive predic-
tive value, negative predictive value, and accuracy for stage N2
TABLE 1. Distribution of Pathological T, N, and IMIG Stages Among Population
No. cases
per TNM Stage Stage T1 T2 T3 T4 N0 N1 N2 N3 IMIG I IMIG II IMIG III IMIG IV
CT group (n = 62) 5 4 43 10 38 6 17 1 5 3 44 10
PET/CT group (n = 26) 1 1 19 5 13 4 8 1 1 1 21 3
FIGURE 1. Computed tomography demonstrating tumor mass
(arrow), staged as N0, with the patient stage N1 by pathology.
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and N3 disease were 70%, 97%, 85%, 88%, and 87% (CT-R1).
Lymph nodes were correctly staged between 42 (CT-R2) and 49
(CT-R1) patients. A large number of pathologic stage N0 were
overestimated (CT-R1: n = 4, CT-R2: n = 6, CT-R3: n = 4). Four
(CT-R1) and 7 patients (CT-R2, CT-R3) with pathological stage
N1/N2 were staged as N0.
Concerning the IMIG classification, the sensitivity, speci-
ficity, positive predictive value, negative predictive value, and
accuracy of CT for IMIG stage IV disease were 50%, 89%,
50%, 89%, and 82% for CT-R1 (Fig. 2). The number of pa-
tients who were understaged was high for IMIG stages III and
IV, with an underestimation of pathological stage III in 5 (CT-
R1), 10 (CT-R2), and 7 patients (CT-R3).
PET/CT
The sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy for stage T4 disease were 80%,
95%, 80%, 95%, and 92% for PET/CT-R2, which is higher when
compared with CT. The number of correct T-stage patients was
20 (PET/CT-R2) and 21(PET/CT-R1/-R3). The tumor extent was
more frequently underestimated than overestimated, but the per-
centage of underestimation was lower compared with CT (PET/
CT: 4%–19%; CT: 22%%–30%), resulting in a higher negative
predictive value and higher accuracy (Tables 3 and 4).
For nodal staging, the stage N sensitivity, specificity, positive
predictive value, negative predictive value, and accuracy for stage
N2 and N3 disease were 80%, 78%, 57%, 91%, and 78% for PET/
CT-R2, which is lower compared with CT. N stage was correctly
assessed in 54% of cases. Concerning underestimation or overes-
timation, no trend was evident (Fig. 3).
The sensitivity, specificity, positive predictive value, negative
predictive value, and accuracy of CT for IMIG stage IV disease
were 66%, 95%, 66%, 95%, and 91% for PET/CT-R2 (Fig. 4).
The interobserver agreement was good for all 3 readers (PET/
CT-R1 to PET/CT-R2: 0.82; PET/CT-R1 to PET/CT-R3: 0.78;
PET/CT-R2 to PET/CT-R3: 0.79).
Comparison Between CT and PET/CT for Patients
Undergoing Both Examinations
Comparing imaging to pathology for each patient individu-
ally, T and N staging was identical in 4 patients on all modalities.
When focusing on IMIG classification, this number increased to
13 patients out of 26, whereas a higher number of cases were
overstaged by CT when compared with PET/CT. N stage was
more often understaged on PET/CT comparedwith CT; especially
pathologic N stage 2 was staged as N0 on PET/CT (Fig. 5).
Interobserver Agreement
For CT-based T staging and N staging, the interobserver
agreement was moderate to good (CT-R1 to CT-R2: 0.73; CT-R1
to CT-R3: 0.52; CT-R2 to CT-R3: 0.48) and fair to moderate
TABLE 2. CT-Based Clinical Staging ComparedWith Pathological
TNM Stages (n = 62)
Reader
Correct,
n (%)
Underestimation,
n (%)
Overestimation,
n (%)
T stage R1 44 (72) 14 (22) 4 (6)
R2 40 (65) 17 (27) 5 (8)
R3 43 (70) 14 (22) 5 (8)
N stage R1 49 (79) 7 (11) 6 (10)
R2 42 (68) 12 (19) 8 (13)
R3 47 (76) 9 (15) 6 (10)
IMIG R1 45 (73) 11 (18) 6 (10)
R2 41 (66) 16 (26) 5 (8)
R3 41 (66) 15 (24) 6 (10)
FIGURE 2. Computed tomography–based clinical IMIG classification for the 3 readers in comparison to pathological IMIG stage.
TABLE 3. PET/CT-Based Clinical Staging Compared With
Pathological Stages (n = 26)
Reader
Correct,
n (%)
Underestimation,
n (%)
Overestimation,
n (%)
T stage PET/CT-R1 21 (81) 4 (15) 1 (4)
PET/CT-R2 20 (77) 5 (19) 1 (4)
PET/CT-R3 21 (81) 1 (4) 4 (15)
N stage PET/CT-R1 13 (50) 6 (23) 7 (27)
PET/CT-R2 14 (54) 6 (23) 6 (23)
PET/CT-R3 15 (58) 7 (27) 4 (15)
IMIG PET/CT-R1 21 (81) 4 (15) 1 (4)
PET/CT-R2 21 (81) 4 (15) 1 (4)
PET/CT-R3 21 (81) 2 (12) 3 (12)
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(CT-R1 to CT-R2: 0.43; CT-R1 to CT-R3: 0.51; CT-R2 to CT-R3:
0.37), respectively.
For PET/CT-based T staging and N staging, the interobserver
agreement was good for both (T staging: PET/CT-R1 to PET/CT-
R2: 0.71; PET/CT-R1 to PET/CT-R3: 0.63; PET/CT-R2 to PET/
CT-R3: 0.64; N staging: PET/CT-R1 to PET/CT-R2: 0.75; PET/
CT-R1 to PET/CT-R3: 0.76; PET/CT-R2 to PET/CT-R3: 0.73).
DISCUSSION
Over the last decade, CTwas commonly used for the initial
evaluation of MPM, but it has limited sensitivity and specificity
for the diagnosis and fails to predict resectability.7 Heelan et al5
compared CT and MRI for staging for MPM and found an ac-
curacy between 55% for invasion of diaphragm and 80% for
mediastinal fat invasion to correspond with stage T3. With the
introduction of new types of CT scanners with higher temporal
and spatial resolution as well as the availability of PET/CT scan-
ning, it has to be assumed that the accuracy for staging the intra-
thoracic extent of MPM should have increased.
In our study, PET/CTand CTunderestimated the local tumor
extent in up to 30% of the cases. Sensitivity and accuracy for
nodal staging were almost equal for CT compared with PET/CT,
although it was often underestimated. Comparing PET/CT to
CT alone, PET/CT improved the accuracy of preoperative IMIG
staging, although the accuracy for N staging remained low for
PET/CT. The higher accuracy for IMIG stage IV classification
with PET/CT compared with CT is mostly based on the combina-
tion of T and N stage among the classes. The IMIG classification
accommodates the low accuracy of lymph node staging by com-
bining N1 and N2 into 1 stage (stage III). This raises the question
of the appropriateness of the T and N descriptors for early-stage
disease, which has also been discussed by Rusch et al6 after the
initial analysis of the IASLC data set.
Computed tomography usually underestimated stage T dis-
ease by classifying actual stage T3 as stage T2, especially in re-
gions of possible pericardial involvement, indicating that newer
scanners still do not allow detection of invasion of the mediastinal
fat accurately as the pleural layers are not visualized and the soft
tissue contrast is reduced compared with MR. Alternatively,
volumetry could replace the T descriptor.4,6,16
A high accuracy for PET/CT has been reported by other stud-
ies.1,3,7 Plathow et al3 evaluated and compared the accuracy of
staging limited MPM between CT, PET/CT, and MRI. Their re-
sults showed a high accuracy for all 3 modalities for tumor IMIG
stages II and III, whereas PET/CT was most accurate. Erasmus
et al7 reported accuracies for the determination of stages T and
N of 63% and 35% (study population n = 29). Stage T disease
was more often understaged (29%) as opposed to overstaged
(7%). The reason for understaging is the low spatial resolution
of PET/CT not enabling the differentiation between T2 and T3
stages. Sørensen et al19 showed that PET/CT improved the accuracy
of preoperative staging compared with CT alone.1 For the pre-
diction of T4 disease, PET/CT had a sensitivity of 78% and speci-
ficity of 100%.
Regarding nodal staging, the accuracy of PET/CTwas lower
compared with CTalone (78%–87%). We considered lymph node
as positive if the short-axis diameter was greater than 1 cm. Our
results show that CT underestimated nodal stages N1 and N2 as
reported by other studies.1,7 Pilling et al20 found an even lower
sensitivity of 11% and accuracy of 66.6%.6 The reason there-
fore is 2-fold: (1) The close relation between primary tumor and
hilar lymph nodes leads to misinterpretation of stage N1 as shown
by other studies.1,3,7 (2) The use of 1 cm as cutoff is too high for
this type of tumor, leading to underestimation. This is in line with
the results of Nambu et al,21 who found a low sensitivity of CT
for the presence of lymph node metastasis of non–small cell lung
cancer using a cutoff of 5 mm. On PET/CT, all N2 nodes that
were not detected also showed no increased fluorodeoxyglucose
uptake. The reason therefore might be the size of metastatic lymph
nodes as shown for CT or microinvasion. The prognostic role
of mediastinal lymph node involvement for MPM in general re-
mains unclear. For mesothelioma, we and other groups feel that
there might be rather direct invasion from adjacent tumor than
lymphatic spread especially of the mammalian group of lymph
nodes.6,22 This would not only lead to classifying this group of pa-
tients differently but also impact therapy decision making as many
centers exclude patients with N2 disease for radical treatment.
This theory is supported by the findings of Rusch et al,6 as in
the IASLC data set analysis, mediastinal lymph node involve-
ment played no independent prognostic role.
TABLE 4. CT- and PET/CT-Based Staging Compared With Pathology for Each Patient (Population n = 26)
T stage N stage IMIG
CT and PET/CT correct R1: n = 17, R2: n = 18 R1: n = 12, R2: n = 13 R1: n = 15, R2: n = 17
CT and PET/CT understaged R1: n = 1, R2: n = 1 R1: n = 3, R2: n = 4 R1: n = 0, R2: n = 0
CT and PET/CT overstaged R1: n = 0, R2: n = 2 R1: n = 4, R2: n = 3 R1: n = 0, R2: n = 0
CT correct, PET/CT understaged R1: n = 3, R2: n = 0 R1: n = 3, R2: n = 3 R1: n = 4, R2: n = 4
CT correct, PET/CT overstaged R1: n = 1, R2: n = 2 R1: n = 1, R2: n = 1 R1: n = 0, R2: n = 1
CTunderstaged, PET/CT correct R1: n = 2, R2: n = 3 R1: n = 2, R2: n = 1 R1: n = 4, R2: n = 2
CT overstaged, PET/CT correct R1: n = 1, R2: n = 0 R1: n = 1, R2: n = 1 R1: n = 3, R2: n = 2
FIGURE 3. Patient with enlarged but FDG-negative lymph node
on PET/CT. Lymph node was removed and pathologically
staged as N2.
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Another imaging method to evaluate the intrathoracic tumor
extent of MPM isMRI. In our study, we did not evaluate the accu-
racy or interobserver agreement of MRI assessing MPM. Never-
theless, several studies have shown that MRI describes the
extent of tumor with high accuracy.3,5,23,24 Heelan et al5 showed
that MRI is superior to CT for the evaluation of local invasion
and the diaphragm. Plathow et al3 compared MRI to PET/CT
and found that MRI is highly accurate in the local delineation of
MPM and almost equal to PET/CT. The advantage of MRI is
the high soft tissue contrast on unenhanced scans, in addition to
the superior enhancement achieved postcontrast. Several studies
have also shown that current sequences allow better delineation
of the lesion and differentiation between pleural effusion, pleural
thickening, and MPM compared with CT.25–27
The interobserver agreement for local tumor extent was
lower (moderate to good) for CT compared with PET/CT showing
a “good” interobserver agreement. For nodal staging, the inter-
observer agreement was “fair to moderate” for CT and improved
to “good” for PET/CT, although the accuracy was lower. The
interobserver agreement for IMIG classification was “good” for
all readers. There is only 1 other study assessing the interob-
server agreement for IMIG classification of MPM. This study
reported higher κ values for IMIG classification compared with
our study.3 The low interobserver agreement for CTand low accu-
racy reflect the limitations of CT to clearly differentiate among the
stages. Although PET/CT has good interobserver agreement and
good accuracy, it still leads to an underestimated clinical stage.
The reason for the good interobserver agreement for IMIG is the
setting of the classification. The combination of TNM stages for
differentiating between IMIG stages II and III increases the
robustness as mentioned before. The higher interobserver agree-
ment in PET/CT favors this imaging modality.
Our study has several limitations. First, the number of pa-
tients undergoing PET/CT and CT in combination was low. In
addition, a large number of stage T3 diseases are represented in
this cohort (19 of 26 patients), which may bias our findings and
results. Nevertheless, our population highlights the known
weaknesses of the current imaging modalities. Second, we had
different readers for CT and PET-CT. This was due to the lack of
expertise for some readers in PET/CT. The third limitation is
concerning the pathology as criterion standard. We are aware
that the pathological samples from surgery are affected by pre-
operative imaging, and therefore the criterion standard is not
truly independent. Nevertheless, it reflects the daily routine.
Fourth, we included patients who underwent talc pleurodesis at
the time of diagnostic biopsy. Although this causes inflammation
FIGURE 4. Positron emission tomography/CT–based clinical IMIG classification for all 3 readers in comparison to pathological IMIG stage.
FIGURE 5. Patient with pathological stage T2. Computed tomography (A) and PET/CT (B) were assessed as stage T1 by all readers.
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that might influence the accuracy of PET/CT staging, Pilling et al
found no significant difference regarding accuracy of intratho-
racic staging.20
In conclusion, PET/CT underestimated the tumor stage in a
substantial number of cases, making invasive staging methods
such as mediastinoscopy still necessary. Regarding the local extent
of the tumor to assess resectability, the inaccuracy of TandN stag-
ing of both methods shows that so far we do not have a reliable
imaging technique, although PET/CT is clearly favored, particu-
larly because of the lower interobserver variability for clinical
staging of MPM compared with CT alone.
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